KR102585108B1 - 세균 감염의 치료를 위한 항미생물성 폴리믹신 - Google Patents

세균 감염의 치료를 위한 항미생물성 폴리믹신 Download PDF

Info

Publication number
KR102585108B1
KR102585108B1 KR1020177019383A KR20177019383A KR102585108B1 KR 102585108 B1 KR102585108 B1 KR 102585108B1 KR 1020177019383 A KR1020177019383 A KR 1020177019383A KR 20177019383 A KR20177019383 A KR 20177019383A KR 102585108 B1 KR102585108 B1 KR 102585108B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
aryl
atoms
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177019383A
Other languages
English (en)
Korean (ko)
Other versions
KR20170086671A (ko
Inventor
미하일 페도로비치 고르디브
진치안 리우
싱하이 왕
젱유 위안
Original Assignee
상하이 미큐알엑스 파마슈티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 미큐알엑스 파마슈티컬 컴퍼니 리미티드 filed Critical 상하이 미큐알엑스 파마슈티컬 컴퍼니 리미티드
Publication of KR20170086671A publication Critical patent/KR20170086671A/ko
Application granted granted Critical
Publication of KR102585108B1 publication Critical patent/KR102585108B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
KR1020177019383A 2014-12-16 2015-12-16 세균 감염의 치료를 위한 항미생물성 폴리믹신 Active KR102585108B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092780P 2014-12-16 2014-12-16
US62/092,780 2014-12-16
PCT/US2015/066210 WO2016100578A2 (en) 2014-12-16 2015-12-16 Antimicrobial polymyxins for treatment of bacterial infections

Publications (2)

Publication Number Publication Date
KR20170086671A KR20170086671A (ko) 2017-07-26
KR102585108B1 true KR102585108B1 (ko) 2023-10-05

Family

ID=55456866

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177019383A Active KR102585108B1 (ko) 2014-12-16 2015-12-16 세균 감염의 치료를 위한 항미생물성 폴리믹신

Country Status (8)

Country Link
US (1) US9771394B2 (cg-RX-API-DMAC10.html)
EP (1) EP3233889B1 (cg-RX-API-DMAC10.html)
JP (1) JP6896628B2 (cg-RX-API-DMAC10.html)
KR (1) KR102585108B1 (cg-RX-API-DMAC10.html)
CN (1) CN107257803B (cg-RX-API-DMAC10.html)
CA (1) CA2970546A1 (cg-RX-API-DMAC10.html)
ES (1) ES2924058T3 (cg-RX-API-DMAC10.html)
WO (1) WO2016100578A2 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189866A1 (en) * 2016-04-27 2017-11-02 Spero Opco Polymyxin analogs useful as antibiotic potentiators
EP3388445A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Peptide macrocycles and use thereof in the treatment of bacterial infections
WO2019084628A1 (en) 2017-11-02 2019-05-09 The University Of Queensland Peptide antibiotics
CA3102833A1 (en) * 2018-06-12 2019-12-19 University Of Manitoba Preparation of dilipid polymyxins and use thereof as antimicrobial adjuvants
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
GB201904534D0 (en) * 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof
US12435108B2 (en) 2019-07-24 2025-10-07 Sunshine Lake Pharma Co., Ltd. Teixobactin analogue and use thereof
CN111072757B (zh) * 2020-01-02 2021-10-15 上海上药第一生化药业有限公司 多黏菌素b组分或其盐及其制备方法和应用
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
WO2023001224A1 (en) * 2021-07-21 2023-01-26 Shanghai Micurx Pharmaceutical Co., Ltd. Novel compounds and compositions for targeted therapy of renal cancers
WO2023001223A1 (en) * 2021-07-21 2023-01-26 Shanghai Micurx Pharmaceutical Co., Ltd. Compounds and compositions for targeted therapy of renal diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
WO2010130007A1 (en) * 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
WO2013072695A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
WO2014188178A1 (en) * 2013-05-22 2014-11-27 Cantab Anti-Infectives Limited Polymyxin derivatives and their use in combination therapy together with different antibiotics

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450687A (en) 1966-02-24 1969-06-17 Pfizer & Co C Lower alkanoyl esters of polymyxin antibiotics
DE1906699A1 (de) 1968-02-12 1970-02-05 Pfizer Neue Polymyxinderivate und Verfahren zu deren Herstellung
US4091092A (en) 1976-09-20 1978-05-23 E. R. Squibb & Sons, Inc. Polymyxin F and process of producing polymyxin F
JPS5831918B2 (ja) 1976-10-27 1983-07-09 塩野義製薬株式会社 新規抗生物質ポリミキシンs↓1
US6380356B1 (en) 1999-12-07 2002-04-30 Advanced Medicine, Inc. Multivalent polymyxin antibiotics
WO2006045156A1 (en) 2004-10-29 2006-05-04 Monash University Therapy for multi-drug resistant microorganisms
KR100750658B1 (ko) 2005-12-09 2007-08-20 한국생명공학연구원 폴리믹신 생합성 효소 및 이를 코딩하는 유전자 군
BRPI0715095B8 (pt) 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
FI20085469A0 (fi) * 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US9096649B2 (en) 2008-02-08 2015-08-04 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8389679B2 (en) 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
NZ598074A (en) 2009-09-01 2014-04-30 Fab Pharma Sas Novel antibacterial hydroxyphenyl compound
JP5353680B2 (ja) 2009-12-18 2013-11-27 船井電機株式会社 光ディスク装置
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
CN103130876B (zh) 2011-11-30 2014-07-23 广东双柏药业有限公司 一种高纯度多粘菌素b的制备方法
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
EP2884989A4 (en) 2012-08-17 2016-03-23 Univ Houston System LIPOSOMAL FORMULATIONS OF POLYMIXIN AND USES THEREOF
EP2909220B1 (en) 2012-10-18 2016-11-23 Dow Global Technologies LLC Phosphorous-containing aluminum carboxylate salt flame retardants
CN103044529B (zh) * 2012-12-06 2018-01-30 山东鲁抗医药股份有限公司 一种在硫酸多粘菌素b中提取b1单组份的方法
CA2895910C (en) 2013-01-11 2021-12-21 Xellia Pharmaceuticals Aps Polymyxins, compositions, methods of making and methods of use
CN103923190B (zh) 2013-01-14 2018-04-03 上海医药工业研究院 从多黏菌素b的混合组分中分离纯化多黏菌素b1的方法
WO2015031602A1 (en) 2013-08-29 2015-03-05 Rhk Technology, Inc. Optical alignment interface
KR20160135739A (ko) * 2014-03-11 2016-11-28 뉴 파마 라이센스 홀딩스 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
WO2010130007A1 (en) * 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
WO2013072695A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
WO2014188178A1 (en) * 2013-05-22 2014-11-27 Cantab Anti-Infectives Limited Polymyxin derivatives and their use in combination therapy together with different antibiotics

Also Published As

Publication number Publication date
US9771394B2 (en) 2017-09-26
JP2018502845A (ja) 2018-02-01
JP6896628B2 (ja) 2021-06-30
ES2924058T3 (es) 2022-10-04
EP3233889B1 (en) 2022-07-06
KR20170086671A (ko) 2017-07-26
CN107257803A (zh) 2017-10-17
EP3233889A2 (en) 2017-10-25
CA2970546A1 (en) 2016-06-23
CN107257803B (zh) 2021-02-05
US20160185823A1 (en) 2016-06-30
WO2016100578A2 (en) 2016-06-23
WO2016100578A3 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
EP3233889B1 (en) Antimicrobial polymyxins for treatment of bacterial infections
EP3445357B1 (en) Bifunctional molecules for degradation of egfr and methods of use
CN114728168B (zh) 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
ES2426641T3 (es) Compuestos indol como inhibidores de la necrosis celular
CA3201793A1 (en) Macrocycles containing a 1,3,4-oxadiazole ring for use as modulators of cystic fibrosis transmembrane conductance regulator
EP3601245A1 (en) Small molecule dcn1 inhibitors and therapeutic methods using the same
CN110546151A (zh) 凋亡诱导剂
AU2018345523A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
JP7403661B2 (ja) Khk阻害効果を有する化合物
KR20120028877A (ko) 리버스턴 유사체의 신규한 화합물 및 그 제조방법과 용도
WO2022223805A1 (en) Modulators of sortilin activity
KR20150088292A (ko) 광범위한 마크로사이클릭 항생제
JP2017516821A (ja) ナフチリジンジオン誘導体
JP2023538768A (ja) 緑膿菌病原性因子LasBの阻害剤
US6465456B2 (en) Isoxazolinone antibacterial agents
JP7723030B2 (ja) チアゾロ[5,4-b]ピリジンMALT-1阻害剤
EP3638681A1 (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria
JP2021504416A (ja) β−ラクタマーゼ阻害剤の結晶形およびその製造方法
WO2018211324A1 (en) Prodrugs for the treatment of disease
CA3239097A1 (en) Prodrugs of boron compounds and their use in treating bacterial infections
JP2004137185A (ja) チオフェン骨格を有する抗菌剤
WO2023001223A1 (en) Compounds and compositions for targeted therapy of renal diseases
JP2017105714A (ja) 多剤排出ポンプ阻害剤
JP2002308870A (ja) チオフェン骨格を有する抗菌剤
RU2782469C2 (ru) Апоптоз-индуцирующие агенты

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4